<DOC>
	<DOCNO>NCT00643071</DOCNO>
	<brief_summary>Patients severe refractory ulcerative colitis ( UC ) receive placebo study F506-CL-1107 receive tacrolimus maximum 12 week . Safety efficacy evaluate .</brief_summary>
	<brief_title>Tacrolimus ( FK506 ) P-III , Open-label Study Refractory Ulcerative Colitis Patients</brief_title>
	<detailed_description>Patients severe refractory ulcerative colitis ( UC ) receive placebo study F506-CL-1107 study participate study . Patients receive tacrolimus maximum 12 week open-label study manner . Improvement Disease Activity Index ( DAI ) score efficacy score evaluate drug administration period .</detailed_description>
	<mesh_term>Ulcer</mesh_term>
	<mesh_term>Colitis , Ulcerative</mesh_term>
	<mesh_term>Colitis</mesh_term>
	<mesh_term>Tacrolimus</mesh_term>
	<criteria>Severe refractory UC patient meet follow criterion Disease activity : 6 time stool day , bloody stool , moderate severe endoscopic find Steroid resistant dependent OR Moderate severe refractory UC patient participate received placebo F506CL1107 study Mild fulminant type Renal failure patient , hepatic failure patient Patients take 6mercaptopurine , cyclosporin immunosuppressant within 12 week prior entry Patients receive LCAP GCAP within 2 week prior entry Patients change dose steroid start steroid within 2 week prior entry Patients change dose steroid start steroid within 1 week prior entry case receive 40 mg/ day 1mg/kg/day steroid study</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>64 Years</maximum_age>
	<verification_date>August 2014</verification_date>
	<keyword>Ulcerative colitis</keyword>
	<keyword>Tacrolimus</keyword>
	<keyword>FK506</keyword>
	<keyword>Treatment outcome</keyword>
</DOC>